Stanislas Niox-Chateau and the Founding of Doctolib
Stanislas Niox-Chateau co-founded Doctolib in 2013 and has led the medical appointment and practice software company since then. The French registered company, Doctolib SAS, lists him as its president since February 2014.
| Role | Co-founder and Chief Executive Officer |
|---|---|
| Company | Doctolib |
| Headquarters | Levallois-Perret, France |
| Industry | Healthcare |
| In role since | 2013 |
| Born | 1987, Paris, France |
| Education | HEC Paris (class of 2010) |
| Company website | about.doctolib.com |
From Junior Tennis to HEC Paris and Otium Capital
Niox-Chateau was ranked number one in France at age 11 and aimed for a professional tennis career, but a serious back injury led him to stop competing at 17. He entered HEC Paris in 2006, served as vice president of its Junior Enterprise and graduated in 2010.
- 2010: joined Otium Capital, the fund he helped launch with Antoine Freysz, and worked on projects including Balinéa
- 2010 to 2013: advised La Fourchette, the restaurant booking platform later bought by Tripadvisor
- 2013: co-founded Doctolib with Jessy Bernal, Ivan Schneider and Steve Abou Rjeily, and became its CEO
What Doctolib Offers Patients and Practitioners
Doctolib runs online appointment booking for patients and software for health professionals in France, Germany and Italy. The platform serves about 50 million people and more than 400,000 practitioners. During the COVID-19 pandemic it became a key booking tool in France, and Niox-Chateau worked regularly with government officials in that period.
Doctolib became a unicorn in March 2019 with a valuation above 1 billion euros, and its March 2022 funding round valued it at 5.8 billion euros. For 2024 Doctolib SAS filed revenue of 253.4 million euros, up from 216.2 million euros in 2023, and the entity lists between 1,000 and 1,999 staff.
Doctolib’s Secondary Share Sale in 2026
In April 2026 employees and early investors sold 345 million dollars of Doctolib shares in a secondary transaction that implied a valuation of about 3.6 billion euros. Doctolib ended 2025 with annual recurring revenue of nearly 422 million euros across the group.
